Medulloblastoma

Common Name(s)

Medulloblastoma

Medulloblastoma is a type of cancerous brain tumor. It is the most common brain tumor in children. The tumor develops in the lower rear part of the brain called the cerebellum. The tumor is fast growing and can spread (malignant), however the cancer usually only spreads within the brain and spinal cord. Medulloblastomas are seen in children under age of 10, but the tumor can be found in adults, most often between the ages of 20-44 years. The exact cause of medulloblastoma is unknown, but mutations or changes in certain genes and chromosomes have been identified which may be involved. Although symptoms vary, common types of symptoms include headaches, vomiting, behavioral and appetite changes, and unusual eye movements. Treatment usually involves surgically removing the tumor, followed by radiation therapy. Chemotherapy may also be used in older children and adults. The prognosis (or outlook) for individuals with a medulloblasoma is looking better as treatments are improving. About 60% of the adults who underwent treatment live five years or more. Outcome for children is even better, reaching up to 80% survival after five years. However, survival rate for infants is poor, with only 50% five year survival rate. Talk with your doctors if you or your child has been diagnosed with a medulloblasoma to undrestand your options and decide on the best treatment plan. Support groups are also a good source of information and support.

Source: Advocacy organizations associated with the condition.

 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Medulloblastoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Medulloblastoma" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Medulloblastoma" returned 768 free, full-text research articles on human participants. First 3 results:

PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
 

Author(s): Alok R Singh, Shweta Joshi, Muamera Zulcic, Michael Alcaraz, Joseph R Garlich, Guillermo A Morales, Yoon J Cho, Lei Bao, Michael L Levy, Robert Newbury, Denise Malicki, Karen Messer, John Crawford, Donald L Durden

Journal:

 

Sonic hedgehog (SHH) medulloblastoma (MB) subtype is driven by a proliferative CD15+ tumor propagating cell (TPC), also considered in the literature as a putative cancer stem cell (CSC). Despite considerable research, much of the biology of this TPC remains unknown. We report evidence ...

Last Updated: 4 Mar 2016

Go To URL
Divergent clonal selection dominates medulloblastoma at recurrence.
 

Author(s): A Sorana Morrissy, Livia Garzia, David J H Shih, Scott Zuyderduyn, Xi Huang, Patryk Skowron, Marc Remke, Florence M G Cavalli, Vijay Ramaswamy, Patricia E Lindsay, Salomeh Jelveh, Laura K Donovan, Xin Wang, Betty Luu, Kory Zayne, Yisu Li, Chelsea Mayoh, Nina Thiessen, Eloi Mercier, Karen L Mungall, Yusanne Ma, Kane Tse, Thomas Zeng, Karey Shumansky, Andrew J L Roth, Sohrab Shah, Hamza Farooq, Noriyuki Kijima, Borja L Holgado, John J Y Lee, Stuart Matan-Lithwick, Jessica Liu, Stephen C Mack, Alex Manno, K A Michealraj, Carolina Nor, John Peacock, Lei Qin, Juri Reimand, Adi Rolider, Yuan Y Thompson, Xiaochong Wu, Trevor Pugh, Adrian Ally, Mikhail Bilenky, Yaron S N Butterfield, Rebecca Carlsen, Young Cheng, Eric Chuah, Richard D Corbett, Noreen Dhalla, An He, Darlene Lee, Haiyan I Li, William Long, Michael Mayo, Patrick Plettner, Jenny Q Qian, Jacqueline E Schein, Angela Tam, Tina Wong, Inanc Birol, Yongjun Zhao, Claudia C Faria, José Pimentel, Sofia Nunes, Tarek Shalaby, Michael Grotzer, Ian F Pollack, Ronald L Hamilton, Xiao-Nan Li, Anne E Bendel, Daniel W Fults, Andrew W Walter, Toshihiro Kumabe, Teiji Tominaga, V Peter Collins, Yoon-Jae Cho, Caitlin Hoffman, David Lyden, Jeffrey H Wisoff, James H Garvin, Duncan S Stearns, Luca Massimi, Ulrich Schüller, Jaroslav Sterba, Karel Zitterbart, Stephanie Puget, Olivier Ayrault, Sandra E Dunn, Daniela P C Tirapelli, Carlos G Carlotti, Helen Wheeler, Andrew R Hallahan, Wendy Ingram, Tobey J MacDonald, Jeffrey J Olson, Erwin G Van Meir, Ji-Yeoun Lee, Kyu-Chang Wang, Seung-Ki Kim, Byung-Kyu Cho, Torsten Pietsch, Gudrun Fleischhack, Stephan Tippelt, Young Shin Ra, Simon Bailey, Janet C Lindsey, Steven C Clifford, Charles G Eberhart, Michael K Cooper, Roger J Packer, Maura Massimino, Maria Luisa Garre, Ute Bartels, Uri Tabori, Cynthia E Hawkins, Peter Dirks, Eric Bouffet, James T Rutka, Robert J Wechsler-Reya, William A Weiss, Lara S Collier, Adam J Dupuy, Andrey Korshunov, David T W Jones, Marcel Kool, Paul A Northcott, Stefan M Pfister, David A Largaespada, Andrew J Mungall, Richard A Moore, Nada Jabado, Gary D Bader, Steven J M Jones, David Malkin, Marco A Marra, Michael D Taylor

Journal: Nature. 2016 Jan;529(7586):351-7.

 

The development of targeted anti-cancer therapies through the study of cancer genomes is intended to increase survival rates and decrease treatment-related toxicity. We treated a transposon-driven, functional genomic mouse model of medulloblastoma with 'humanized' in vivo therapy ...

Last Updated: 21 Jan 2016

Go To URL
[MRI diagnosis of spinal metastasis of medulloblastoma. A clinical case and literature review].
 

Author(s): S S Ozerov, G V Tereshchenko, A V Artemov, E V Kumirova, A E Samarin, L I Papusha, N S Grachev, O G Zheludkova

Journal: Zh Vopr Neirokhir Im N N Burdenko. 2015 ;79(5):72-6; discussion 76.

 

the study objective was to improve the quality of detection of medulloblastoma metastases.

Last Updated: 4 Nov 2015

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Medulloblastoma" returned 43 free, full-text review articles on human participants. First 3 results:

The role of the ubiquitin proteasome system in cerebellar development and medulloblastoma.
 

Author(s): Jerry Vriend, Saeid Ghavami, Hassan Marzban

Journal:

 

Cerebellar granule cells precursors are derived from the upper rhombic lip and migrate tangentially independent of glia along the subpial stream pathway to form the external germinal zone. Postnatally, granule cells migrate from the external germinal zone radially through the Purkinje ...

Last Updated: 17 Oct 2015

Go To URL
Medulloblastoma development: tumor biology informs treatment decisions.
 

Author(s): Vidya Gopalakrishnan, Rong-Hua Tao, Tara Dobson, William Brugmann, Soumen Khatua

Journal: CNS Oncol. 2015 ;4(2):79-89.

 

Medulloblastoma is the most common malignant pediatric brain tumor. Current treatments including surgery, craniospinal radiation and high-dose chemotherapy have led to improvement in survival. However, the risk for recurrence as well as significant long-term neurocognitive and endocrine ...

Last Updated: 15 Mar 2015

Go To URL
Management of pediatric and adult patients with medulloblastoma.
 

Author(s): Allison M Martin, Eric Raabe, Charles Eberhart, Kenneth J Cohen

Journal: Curr Treat Options Oncol. 2014 Dec;15(4):581-94.

 

Approximately 70 % of newly diagnosed children with medulloblastoma (MB) will be classified as "standard risk": their tumor is localized to the posterior fossa, they undergo a near or gross total resection, the tumor does not meet the criteria for large cell/anaplastic histology, ...

Last Updated: 31 Oct 2014

Go To URL
 
 
Top

Symptoms, Diagnosis, and Treatment

There are currently no related results available in Genetics Home Reference.

There are currently no related results available in GeneReviews.

 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
 

Status: Recruiting

Condition Summary: Medulloblastoma

 

Last Updated: 10 Aug 2016

Go to URL
Vaccine Immunotherapy for Recurrent Medulloblastoma and Primitive Neuroectodermal Tumor
 

Status: Recruiting

Condition Summary: Medulloblastoma; Neuroectodermal Tumor

 

Last Updated: 31 May 2016

Go to URL

Last Updated: 28 Jul 2016

Go to URL